From USFDA
Alembic Pharmaceuticals has received approval from USFDA for its Abbreviated New Drug Application for Doxycycline Capsules USP, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Monodox Capsules, 75 mg and 100 mg of Aqua Pharmaceuticals. Doxycycline Capsules are indicated for the treatment and prevention of infections that a proven or strongly suspected to be caused by bacteria.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
